After Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast Instead

Conexeu Sciences Inc. (NASDAQ: CNXU), which commenced Nasdaq trading on May 21, 2026, announced on May 27, 2026 that it has initiated a preclinical development program with the Wake Forest Institute for Regenerative Medicine to evaluate its 3D-bioprinted B.R.E.A.S.T.™ tissue matrix for regenerative breast reconstruction.